Kelly E. Westbrook, MD, discusses combatting tumor heterogeneity in patients with HER2-positive breast cancer.
Kelly E. Westbrook, MD
Advertisement
Articles by Kelly E. Westbrook, MD
Kelly E. Westbrook, MD, discusses the 3-year follow-up data on the KRISTINE trial in stage II or III HER2-positive breast cancer.
Advertisement
Latest Updated Articles
Dr. Westbrook on 3-Year Follow-Up Data of the KRISTINE Trial in HER2+ Breast CancerPublished: September 20th 2019 | Updated:
Dr. Westbrook on Combatting Tumor Heterogeneity in HER2+ Breast CancerPublished: October 9th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5